Sign In
Buy AORT
$26.83
-0.84 (-3.04%)
At Close: Jul 31, 2026
Artivion to Participate in the Stifel 2025 Healthcare Conference
04:10pm, Wednesday, 29'th Oct 2025
ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
04:10pm, Thursday, 23'rd Oct 2025
ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial result
30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data fro
Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
05:03pm, Wednesday, 10'th Sep 2025
Artivion, Inc. (NYSE:AORT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants James Mackin - Chairman, President & CEO Lance Berry - COO, CFO
Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
04:10pm, Friday, 05'th Sep 2025
ATLANTA , Sept. 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming
Share Growth And Strong Clinical Results Continue To Support The Artivion Story
07:47am, Wednesday, 03'rd Sep 2025
Artivion continues to outperform with double-digit revenue growth, strong clinical results, and share gains in niche cardiology markets despite a challenging med-tech environment. New products like AM
Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript
02:30pm, Friday, 08'th Aug 2025
Artivion, Inc. (NYSE:AORT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Lance A. Berry - Executive VP of Finance & CFO Pat MacKin - Corporate Participant Conference
Artivion (AORT) Tops Q2 Earnings and Revenue Estimates
07:06pm, Thursday, 07'th Aug 2025
Artivion (AORT) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.07 per share a year ago.
Artivion (AORT) Q2 EPS Jumps 243%
05:23pm, Thursday, 07'th Aug 2025
Artivion (AORT) Q2 EPS Jumps 243%
Artivion Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Wednesday, 30'th Jul 2025
ATLANTA , July 30, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results
04:10pm, Thursday, 24'th Jul 2025
ATLANTA , July 24, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025 financial resu
NEWTOWN, Pa., July 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Artivion, Inc. (“Artivion”).
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Tuesday, 03'rd Jun 2025
ATLANTA , June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i
ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to pr
